tumours

A potential breakthrough in cancer treatment, using magnetism to guide medication-carrying bacteria into tumours, will be tested in a new JGH lab.

Construction is under way to install a fourth linear accelerator in Radiation Oncology, making cancer treatment faster and more accurate.

Dr. April Rose has joined the JGH as Attending Staff in the Division of Medical Oncology and in the Segal Cancer Centre.

Dr. Michael Pollak, Director of the Stroll Cancer Prevention Centre at the JGH, has been chosen to serve as one of two leaders of a new Canada-wide team, aimed at translating fundamental research about breast cancer into effective treatment options for patients.

The JGH has become the first hospital in Canada to perform an advanced type of robotic surgery for gynecologic cancer, in which all of the medical instruments are inserted into the abdomen via a single, tiny incision in the navel.

A unique phase 2 clinical trial, led by researchers in the Segal Cancer Centre at the JGH, has resulted in a remission of diffuse large B-cell lymphoma for patients who have relapsed and have a particularly dire prognosis.

The Segal Cancer Centre is taking “one small step” that could lead to “one giant leap” in a metaphorical moonshot to conquer cancer.

A key to understanding the formation of the most aggressive type of brain tumour in adults has been revealed at the JGH.

The Segal Cancer Centre at the JGH has distinguished itself as the only medical centre in Quebec to serve the needs of adolescents and young adults with cancer by providing a dedicated clinic staffed by a multi-disciplinary team.

Dr. Christoph Borchers has established the first pan-Canadian proteomics program, custom-tailoring cancer treatments to meet the needs of individual patients